Results 41 to 50 of about 827 (180)

Sulbactam-durlobactam: A Step Forward in Treating Carbapenem-Resistant Acinetobacter baumannii (CRAB) Infections

Clinical Infectious Diseases, 2023
Abstract Antimicrobial resistance in gram-negative pathogens, such as Acinetobacter baumannii, is a serious threat to human health. Sulbactam-durlobactam, a unique β-lactam and a β-lactamase inhibitor combination, is a novel agent targeted against carbapenem-resistant A. baumannii. This supplement provides a summary of the development of
Watkins, Richard R, Bonomo, Robert A
openaire   +2 more sources

In vitro and in vivo evaluation of two combined β-lactamase inhibitors against carbapenem-resistant Acinetobacter baumannii [PDF]

, 2023
The objective of this study was to evaluate the in vitro and in vivo efficacy of clavulanic acid (C/A) in combination with tazobactam against clinical strains of carbapenem-resistant Acinetobacter baumannii. The MIC of 24 clinical strains of A. baumannii
Vila Domínguez, Andrea, Molina Panadero, Irene, Smani, Younes   +2 more
core   +1 more source

In Vivo Emergence of Pandrug-Resistant Acinetobacter baumannii Strain: Comprehensive Resistance Characterization and Compassionate Use of Sulbactam-Durlobactam. [PDF]

Open Forum Infect Dis, 2023
Abstract The treatment of patients with infection secondary to carbapenem-resistant Acinetobacter baumannii with emerging cefiderocol resistance remains challenging and unclear. We present a case of in vivo emergence of pandrug-resistant A baumannii that was successfully treated with the compassionate use of investigational sulbactam ...
VanNatta M, Grier L, Khan MH, Pinargote Cornejo P, Alam M, Moussa SH, Smith JG, Aitken SL, Malek AE.   +8 more
europepmc   +3 more sources

In Vitro Activity of Sulbactam–Durlobactam against Carbapenem-Resistant Acinetobacter baumannii Clinical Isolates: A Multicentre Report from Italy

Antibiotics, 2022
In the present study, the in vitro activity of the sulbactam–durlobactam (SUL–DUR) combination was evaluated against 141 carbapenem-resistant A. baumannii (CRAb) clinical strains collected from six Italian laboratories.
Bernardetta Segatore, Alessandra Piccirilli, Sabrina Cherubini, Luigi Principe, Giovanni Alloggia, Maria Lina Mezzatesta, Mario Salmeri, Stefano Di Bella, Roberta Migliavacca, Aurora Piazza, Elisa Meroni, Paolo Fazii, Daniela Visaggio, Paolo Visca, Venere Cortazzo, Giulia De Angelis, Arianna Pompilio, Mariagrazia Perilli   +17 more
doaj   +1 more source

Sulbactam-durlobactam: a β-lactam/β-lactamase inhibitor combination targeting Acinetobacter baumannii. [PDF]

Future Microbiol
Sulbactam-durlobactam is a pathogen-targeted β-lactam/β-lactamase inhibitor combination that has been approved by the US FDA for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex (ABC) in patients 18 years of age and older.
McLeod SM, O'Donnell JP, Narayanan N, Mills JP, Kaye KS.   +4 more
europepmc   +3 more sources

In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii

Journal of Antimicrobial Chemotherapy, 2020
AbstractObjectivesTo evaluate the activity of the novel broad-spectrum serine β-lactamase inhibitor durlobactam (ETX2514) combined with sulbactam against global isolates of carbapenem-resistant Acinetobacter baumannii with defined carbapenem resistance mechanisms compared with reference antimicrobials with known activity against Acinetobacter spp ...
Harald Seifert, Carina Müller, Danuta Stefanik, Paul G Higgins, Alita Miller, Michael Kresken   +5 more
openaire   +2 more sources

In vitro activity of sulbactam/durlobactam against clinical isolates of Acinetobacter baumannii collected in China

Journal of Antimicrobial Chemotherapy, 2020
AbstractBackgroundDurlobactam is a broad-spectrum inhibitor of class A, C and D β-lactamases. Sulbactam is a generic β-lactam most commonly used as a β-lactamase inhibitor in combination with ampicillin; however, it has a unique property in that it has selective intrinsic activity against Acinetobacter baumannii.
Harald Reinhart, Patricia A Bradford, Meredith Hackel, Jun Deng, Ge Zhang, Jingjia Zhang, Ying Zhu, Peiyao Jia, Yingchun Xu, Qiwen Yang   +9 more
openaire   +2 more sources

Definitions of Urinary Tract Infection in Current Research: A Systematic Review [PDF]

, 2023
Urinary tract infection definitions used in current research studies are highly heterogeneous in terms of clinical signs and diagnostic tests. Few studies meet symptom, pyuria, and urine culture criteria mentioned in existing research guidelines.Defining
Bilsen Manu P., Caterino Jeffrey M., Conroy Simon P., Geerlings Suzanne E., Jongeneel Rosa M. H., Köves Béla, Lambregts Merel M. C., Mody Lona, Platteel Tamara N., Schneeberger Caroline, van Nieuwkoop Cees, Visser Leo G., Wagenlehner Florian   +12 more
core   +4 more sources

Antibiotics needed to treat multidrug-resistant infections in neonates. [PDF]

, 2022
Infections remain a leading cause of death in neonates. The sparse antibiotic development pipeline and challenges in conducting neonatal research have resulted in few effective antibiotics being adequately studied to treat multidrug-resistant (MDR ...
Agarwal, R, Balasegaram, M, Bielicki, JA, Bradley, J, Ellis, S, Giaquinto, C, Nambiar, S, Noel, GJ, O'Brien, S, Qazi, SA, Sharland, M, Velaphi, S, Williams, PC   +12 more
core   +1 more source

Failure of durlobactam to restore the susceptibility to meropenem in carbapenem-resistant Klebsiella pneumoniae

Journal of Global Antimicrobial Resistance
Objective: Durlobactam, a diazabicyclooctane β-lactamase inhibitor, can protect meropenem from hydrolysis of KPC and OXA-48 carbapenemases. This study aims to characterise the genome of a carbapenem-resistant Klebsiella pneumoniae clinical strain with a ...
Hongxia Wen, Yu Feng, Zhiyong Zong
doaj   +1 more source